|
Aug 6
|
Minerva Neurosciences: Q2 Earnings Snapshot
|
|
Aug 6
|
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
|
|
May 6
|
Minerva Neurosciences (NERV) Upgraded to Buy: What Does It Mean for the Stock?
|
|
May 1
|
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
|
|
Feb 27
|
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
|
|
Feb 27
|
Minerva schizophrenia drug rejected by FDA
|
|
Feb 22
|
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
|
|
Nov 7
|
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
|
|
Jun 28
|
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
|